The KLF4 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human 143B osteosarcoma cells carrying targeted disruption of the KLF4 gene. This loss-of-function model provides a heterogeneous pool of edited cells, circumventing clonal bias and enabling robust functional genomics studies. The polyclonal format is particularly suited for investigating broad transcriptional effects of KLF4 ablation in a high-grade osteosarcoma background, offering a versatile tool for dissecting its context-dependent roles in tumor biology.
The 143B cell line is a well-characterized human osteosarcoma model with high tumorigenic and metastatic potential, widely employed to study bone cancer progression. It exhibits aggressive in vitro and in vivo behavior, including rapid proliferation and motility, making it an ideal host for examining genes involved in metastasis and epithelial-mesenchymal transition (EMT). The 143B background provides a physiologically relevant system to assess how KLF4 loss influences osteosarcoma aggressiveness.
KLF4 is a zinc finger transcription factor that binds GC-rich sequences to regulate cell cycle, apoptosis, and differentiation. It is activated by TGF-??1 through SMAD2/3/4 signaling and is also regulated by EGF, Wnt3a, insulin, and p53. KLF4 directly transactivates CDKN1A (p21) and CDH1 (E-cadherin) while repressing CCND1 (cyclin D1) and VIM (vimentin), thereby promoting cell cycle arrest and maintaining epithelial phenotype. It interacts with POU5F1 (Oct4), SOX2, and MYC, forming complexes essential for pluripotency and cell fate decisions. In osteosarcoma, KLF4 deficiency disrupts these controls, potentially enhancing EMT and metastatic behavior.
In 143B cells, KLF4 knockout is predicted to reduce p21 and E-cadherin expression, impairing G1/S checkpoint arrest and fostering a mesenchymal, invasive phenotype. This model therefore enables detailed investigation of KLF4’s tumor suppressor or oncogenic functions in osteosarcoma, particularly its interplay with TGF-?? and p53 pathways. It serves as a relevant platform for studying how transcriptional dysregulation drives bone cancer metastasis and for screening compounds that may restore or mimic KLF4 activity.
Research applications encompass western blotting and RT-qPCR for expression analysis, proliferation (MTS) and transwell migration/invasion assays for phenotypic assessment, and flow cytometry for apoptosis and cell cycle profiling. In vivo xenograft tumor growth studies evaluate metastatic potential, while RNA-seq and ChIP-qPCR delineate genome-wide transcriptional changes and direct target occupancy. These polyclonal cells support osteosarcoma metastasis research, transcription factor functional characterization, cancer stem cell studies, drug resistance mechanism dissection, and tumor microenvironment investigations. For additional details, please contact Ascent Research.
